Warner Chilcott Sues Watson for Infringement of Loestrin(R) 24 Fe Patent

    FAJARDO, Puerto Rico, July 31 /PRNewswire/ -- Warner Chilcott Company,
 Inc. announced today that it has filed suit against Watson Laboratories,
 Inc. and Watson Pharmaceuticals, Inc. in the United States District Court
 for the District of New Jersey alleging infringement of Warner Chilcott's
 U.S. patent that protects Loestrin(R) 24 Fe.
     The lawsuit is in response to an Abbreviated New Drug Application filed
 by Watson with the FDA regarding Watson's intent to market a generic
 version of Loestrin(R) 24 Fe prior to the expiration of Warner Chilcott's
 U.S. Patent No. 5,552,394.
     Warner Chilcott has full confidence in, and will continue to vigorously
 defend and enforce, its intellectual property rights protecting Loestrin(R)
 24 Fe.
     The Company
     Warner Chilcott is a leading specialty pharmaceutical company focused
 on developing, manufacturing and marketing and selling branded prescription
 products in women's healthcare and dermatology in the United States.
     Forward Looking Statements
     This press release contains forward-looking statements, including
 statements concerning our operations, our economic performance and
 financial condition, and our business plans and growth strategy and product
 development efforts. These statements constitute forward-looking statements
 within the meaning of Section 27A of the Securities Act of 1933 and Section
 21E of the Securities Exchange Act of 1934. The words "may," "might,"
 "will," "should," "estimate," "project," "plan," "anticipate," "expect,"
 intend," "outlook," "believe" and other similar expressions are intended to
 identify forward- looking statements. Readers are cautioned not to place
 undue reliance on these forward-looking statements, which speak only as of
 their dates. These forward-looking statements are based on estimates and
 assumptions by our management that, although we believe to be reasonable,
 are inherently uncertain and subject to a number of risks and
 uncertainties.
     The following represent some, but not necessarily all, of the factors
 that could cause actual results to differ from historical results or those
 anticipated or predicted by our forward-looking statements: our substantial
 indebtedness; competitive factors in the industry in which we operate; our
 ability to protect our intellectual property; a delay in qualifying our
 manufacturing facility to produce our products or production or regulatory
 problems with either third party manufacturers upon whom we may rely for
 some of our products or our own manufacturing facility; pricing pressures
 from reimbursement policies of private managed care organizations and other
 third party payors, government sponsored health systems, the continued
 consolidation of the distribution network through which we sell our
 products, including wholesale drug distributors and the growth of large
 retail drug store chains; the loss of key senior management or scientific
 staff; an increase in litigation, including product liability claims and
 patent litigation; government regulation affecting the development,
 manufacture, marketing and sale of pharmaceutical products, including our
 ability and the ability of companies with whom we do business to obtain
 necessary regulatory approvals; our ability to successfully complete the
 implementation of a company-wide enterprise resource planning system
 without disrupting our business; our ability to manage the growth of our
 business by successfully identifying, developing, acquiring or licensing
 and marketing new products, obtain regulatory approval and customer
 acceptance of those products, and continued customer acceptance of our
 existing products; and other risks detailed from time-to-time in our
 financial statements and other investor communications.
     We caution you that the foregoing list of important factors is not
 exclusive. In addition, in light of these risks and uncertainties, the
 matters referred to in our forward-looking statements may not occur. We
 undertake no obligation to publicly update or revise any forward-looking
 statement as a result of new information, future events or otherwise,
 except as may be required by law.
 
 

SOURCE Warner Chilcott Company, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.